Get started
Author

Vivek K. Vyas

Observed names: V. K. Vyas, V.K. Vyas, VK Vyas, Vivek K. Vyas, Vivek K Vyas, Vivek K. Vays, Vivek Kumar Vyas, Vivek Vyas, Vyas Vivek, Vyas, V. K., Vyas, V.K., Vyas, Vivek K., Vyas, Vivek Kumar
Institution: Nirma University
ORCID: 0000-0002-7800-0647
Observed ORCID: 0000-0002-7800-0647
OpenAlex ID: A5007456590
Homology modeling a fast tool for drug discovery: Current perspectives
2012 · VK Vyas, RD Ukawala, et al. · Indian Journal of Pharmaceutical Sciences · 281
PDF
Therapeutic potential of snake venom in cancer therapy: current perspectives
2013 · Vivek Kumar Vyas, Keyur Brahmbhatt, et al. · Asian Pacific Journal of Tropical Biomedicine · 169
PDF
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
2011 · V. K. Vyas, M. Ghate · Mini-Reviews in Medicinal Chemistry · 143
Virtual Screening: A Fast Tool for Drug Design
2008 · Vivek Vyas · Scientia Pharmaceutica · 100
PDF
Synthesis, anti-inflammatory, analgesic, 5-lipoxygenase (5-LOX) inhibition activities, and molecular docking study of 7-substituted coumarin derivatives
2016 · Pavan Srivastava, Vivek K. Vyas, et al. · Bioorganic Chemistry · 99
Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors
2013 · Vivek K. Vyas, Manjunath Ghate, et al. · Journal of Molecular Graphics and Modelling · 69
Capillary electrophoresis methods for impurity profiling of drugs: A review of the past decade
2021 · Mansi Shah, Nrupesh Patel, et al. · Journal of Pharmaceutical Analysis · 59
PDF
Neuroprotective Effects of Ethyl Pyruvate against Aluminum Chloride-Induced Alzheimer’s Disease in Rats via Inhibiting Toll-Like Receptor 4
2020 · Vijaya Durga Chavali, Milee Agarwal, et al. · Journal of Molecular Neuroscience · 52
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders
2021 · Piyush Gediya, Palak K. Parikh, et al. · European Journal of Medicinal Chemistry · 48
Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review
2010 · V. K. Vyas, M. Ghate · Mini-Reviews in Medicinal Chemistry · 45
CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer
2019 · Dhara M. Chhatbar, Udit J. Chaube, et al. · Computational Biology and Chemistry · 43
Hybrid Quantum Mechanics/Molecular Mechanics (QM/MM) Simulation: A Tool for Structure-Based Drug Design and Discovery
2021 · Prajakta U. Kulkarni, Harshil Shah, et al. · Mini-Reviews in Medicinal Chemistry · 41
Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review
2022 · Pinky Gehlot, Sunil Kumar, et al. · Bioorganic & Medicinal Chemistry · 40
Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents
2014 · Vivek K. Vyas, Bhavesh Variya, et al. · European Journal of Medicinal Chemistry · 38
Ligand and structure-based approaches for the identification of SIRT1 activators
2015 · Vivek K. Vyas, Ashutosh Goel, et al. · Chemico-Biological Interactions · 36
A Review on Forced Degradation Strategies to Establish the Stability of Therapeutic Peptide Formulations
2023 · Shikha Patel, Vivek K. Vyas, et al. · International Journal of Peptide Research and Therapeutics · 35
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity
2016 · Shraddha V. Bhadada, Vivek K. Vyas, et al. · Biomedicine & Pharmacotherapy · 34
Effects of eugenol on the behavioral and pathological progression in the MPTP-induced Parkinson's disease mouse model
2022 · Urmi Vora, Vivek Kumar Vyas, et al. · Drug Discoveries & Therapeutics · 32
PDF
Structure- and ligand-based drug design methods for the modeling of antimalarial agents: a review of updates from 2012 onwards
2021 · Vivek K. Vyas, Sapna Bhati, et al. · Journal of Biomolecular Structure and Dynamics · 29
CoMFA and CoMSIA studies onC-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
2013 · V. K. Vyas, H. G. Bhatt, et al. · SAR and QSAR in environmental research · 27
Combined in silico approaches for the identification of novel inhibitors of human islet amyloid polypeptide (hIAPP) fibrillation
2017 · Palak Patel, Krupali Parmar, et al. · Journal of Molecular Graphics and Modelling · 26
Therapeutic potential of 4-substituted coumarins: A conspectus
2022 · Manmohan Sharma, Vivek K. Vyas, et al. · European Journal of Medicinal Chemistry Reports · 24
PDF
Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design
2019 · Vivek K. Vyas, Gulamnizami Qureshi, et al. · Bioorganic & Medicinal Chemistry Letters · 24
Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity
2016 · V. K. Vyas, G. Qureshi, et al. · SAR and QSAR in environmental research · 21
A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)
2024 · Pinky Gehlot, Rekha Pathak, et al. · Bioorganic & Medicinal Chemistry · 20
Works count: 103
Citation count: 2,038
H-index: 23
I10-index: 48
Year
Topic
Type